LSNE Contract Manufacturing expanded vial filling and lyophilization capacity with the addition of a new automated aseptic fill line, housed in an existing ISO-5 clean room suite at its facility in Bedford, NH. The multi-product fill line serves to increase capacity and flexibility for manufacturing high-value APIs to meet the demand in drug product manufacturing driven by the Covid-19 pandemic.
 
This manufacturing suite is designed to support products that require minimal process loss because of API availability or high cost. The new fill suite features in-line (non-destructive) weight checks and fully disposable formulation and manufacturing materials, minimizing line loss and conserving product for every batch. The new fill suite is scheduled to be qualified and ready for contract cGMP manufacturing in 3Q21 increasing LSNE’s capacity by up to 100 additional aseptic manufacturing lots per year. 
 
“LSNE continues to innovate and expand our global capacity and capabilities to better serve pharmaceutical companies with their ever changing clinical and commercial programs. By investing in this new GMP sterile fill finish capacity on our Bedford, New Hampshire campus, we continue to execute on our corporate growth strategy and better serve our client’s needs, especially where product loss is a key consideration,” said Shawn Cain, Chief Operating Officer.